Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir

Reviews in Medical Virology

Volumn 19, Issue 4, 2009, Pages 215-229

  Prichard, Mark N ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAVIR; CYCLIN DEPENDENT KINASE 1; ELONGATION FACTOR 1; ELONGATION FACTOR 1 DELTA; GANCICLOVIR; LAMIN A; LAMIN C; NUCLEOSIDE ANALOG; PROTEIN KINASE UL97; RETINOBLASTOMA PROTEIN; RNA POLYMERASE II; ROSCOVITINE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENZYME;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CARBOXY TERMINAL SEQUENCE; DNA SYNTHESIS; DRUG EFFICACY; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; HUMAN CYTOMEGALOVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN PHOSPHORYLATION; REVIEW; STRAIN DIFFERENCE; VIRION; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS MORPHOGENESIS; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS STRAIN;

AMINO ACID SEQUENCE; BENZIMIDAZOLES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA REPLICATION; DNA, VIRAL; HUMANS; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RIBONUCLEOSIDES; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 67650911368     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.615     Document Type: Review

References (150)

1. Cunningham C, Davison AJ, Dolan A, et al. The UL13 virion protein of herpes simplex virus type 1 is phosphorylated by a novel virus-induced protein kinase. J Gen Virol 1992; 73(Pt 2): 303-311.
2. Overton HA, McMillan DJ, Klavinskis LS, Hope L, Ritchie AJ, Wong-kai-in P. Herpes simplex virus type 1 gene UL13 encodes a phosphoprotein that is a component of the virion. Virology 1992; 190(1): 184-192.
3. Stevenson D, Colman KL, Davison AJ. Characterization of the putative protein kinases specified by varicella-zoster virus genes 47 and 66. J Gen Virol 1994; 75(Pt 2): 317-326.
4. van Zeijl M, Fairhurst J, Baum EZ, Sun L, Jones TR. The human cytomegalovirus UL97 protein is phosphorylated and a component of virions. Virology 1997; 231(1): 72-80.
5. Gershburg E, Pagano JS. Conserved herpesvirus protein kinases. Biochim Biophys Acta 2008; 1784(1): 203-212.
6. Michel D, Mertens T. The UL97 protein kinase of human cytomegalovirus and homologues in other herpesviruses: impact on virus and host. Biochim Biophys Acta 2004; 1697(1-2): 169-180.
7. Kawaguchi Y, Kato K, Tanaka M, Kanamori M, Nishiyama Y, Yamanashi Y. Conserved protein kinases encoded by herpesviruses and cellular protein kinase cdc2 target the same phosphorylation site in eukaryotic elongation factor 1delta. J Virol 2003; 77(4): 2359-2368.
8. Chee MS, Lawrence GL, Barrell BG. Alpha-, beta-and gammaherpesviruses encode a putative phosphotransferase. J Gen Virol 1989; 70(Pt 5): 1151-1160.
9. Lawrence GL, Chee M, Craxton MA, Gompels UA, Honess RW, Barrell BG. Human herpesvirus 6 is closely related to human cytomegalovirus. J Virol 1990; 64(1): 287-299.
10. Chen MR, Chang SJ, Huang H, Chen JY. A protein kinase activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral early antigen EA-D in vitro. J Virol 2000; 74(7): 3093-3104.
11. McGeoch DJ, Davison AJ. Alphaherpesviruses possess a gene homologous to the protein kinase gene family of eukaryotes and retroviruses. Nucleic Acids Res. 1986; 14(4): 1765-1777.
12. Megaw AG, Rapaport D, Avidor B, Frenkel N, Davison AJ. The DNA sequence of the RK strain of human herpesvirus 7. Virology 1998; 244(1): 119-132.
13. Russo JJ, Bohenzky RA, Chien MC, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpes-virus (HHV8). Proc Natl Acad Sci U S A 1996; 93(25): 14862-14867.
14. Heineman TC, Seidel K, Cohen JI. The varicella-zoster virus ORF66 protein induces kinase activity and is dispensable for viral replication. J Virol 1996; 70(10): 7312-7317.
15. Purves FC, Longnecker RM, Leader DP, Roizman B. Herpes simplex virus 1 protein kinase is encoded by open reading frame US3 which is not essential for virus growth in cell culture. J Virol 1987; 61(9): 2896-2901.
16. L protein kinases (herpesviruses). In The Protein Kinase Facts Book, Hardie DG, Hanks S (eds). Academic Press: London, UK, 1995.
17. Purves FC, Roizman B. The UL13 gene of herpes simplex virus 1 encodes the functions for posttranslational processing associated with phosphorylation of the regulatory protein alpha 22. Proc Natl Acad Sci U S A 1992; 89(16): 7310-7314.
18. Heineman TC, Cohen JI. The varicella-zoster virus (VZV) open reading frame 47 (ORF47) protein kinase is dispensable for viral replication and is not required for phosphorylation of ORF63 protein, the VZV homolog of herpes simplex virus ICP22. J Virol 1995; 69(11): 7367-7370.
19. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992; 358(6382): 160-162.
20. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992; 358(6382): 162-164.
21. Ansari A, Emery VC. The U69 gene of human herpesvirus 6 encodes a protein kinase which can confer ganciclovir sensitivity to baculoviruses. J Virol 1999; 73(4): 3284-3291.
22. Park J, Lee D, Seo T, Chung J, Choe J. Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) open reading frame 36 protein is a serine protein kinase. J Gen Virol 2000; 81(Pt 4): 1067-1071.
23. Romaker D, Schregel V, Maurer K, Auerochs S, Marzi A, Sticht H, Marschall M. Analysis of the structure-activity relationship of four herpesviral UL97 subfamily protein kinases reveals partial but not full functional conservation. J Med Chem 2006; 49(24): 7044-7053.
24. Smith RF, Smith TF. Identification of new protein kinase-related genes in three herpesviruses, herpes simplex virus, varicella-zoster virus, and Epstein-Barr virus. J Virol 1989; 63(1): 450-455.
25. Prichard MN, Gao N, Jairath S, et al. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J Virol 1999; 73(7): 5663-5670.
26. Moffat JF, Zerboni L, Sommer MH, et al. The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse. Proc Natl Acad Sci U S A 1998; 95(20): 11969-11974.
27. Shibaki T, Suzutani T, Yoshida I, Ogasawara M, Azuma M. Participation of type I interferon in the decreased virulence of the UL13 gene-deleted mutant of herpes simplex virus type 1. J Interferon Cytokine Res 2001; 21(5): 279-285.
28. He Z, He YS, Kim Y, et al. The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. J Virol 1997; 71(1): 405-411.
29. Hamza MS, Reyes RA, Izumiya Y, Wisdom R, Kung HJ, Luciw PA. ORF36 protein kinase of Kaposi's sarcoma herpesvirus activates the c-Jun N-terminal kinase signaling pathway. J Biol Chem 2004; 279(37): 38325-38330.
30. Kato A, Yamamoto M, Ohno T, et al. Herpes simplex virus 1-encoded protein kinase UL13 phosphorylates viral Us3 protein kinase and regulates nuclear localization of viral envelopment factors UL34 and UL31. J Virol 2006; 80(3): 1476-1486.
31. Asai R, Ohno T, Kato A, Kawaguchi Y. Identification of proteins directly phosphorylated by UL13 protein kinase from herpes simplex virus 1. Microbes Infect 2007; 9(12-13): 1434-1438.
32. Purves FC, Spector D, Roizman B. The herpes simplex virus 1 protein kinase encoded by the US3 gene mediates posttranslational modification of the phosphoprotein encoded by the UL34 gene. J Virol 1991; 65(11): 5757-5764.
33. Kenyon TK, Lynch J, Hay J, Ruyechan W, Grose C. Varicella-zoster virus ORF47 protein serine kinase: characterization of a cloned, biologically active phosphotransferase and two viral substrates, ORF62 and ORF63. J Virol 2001; 75(18): 8854-8858.
34. Reddy SM, Cox E, Iofin I, Soong W, Cohen JI. Varicella-zoster virus (VZV) ORF32 encodes a phosphoprotein that is posttranslationally modified by the VZV ORF47 protein kinase. J Virol 1998; 72(10): 8083-8088.
35. Gershburg E, Pagano JS. Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94. J Virol 2002; 76(3): 998-1003.
36. Kamil JP, Coen DM. Human cytomegalovirus protein kinase UL97 forms a complex with the tegument phosphoprotein pp65. J Virol 2007; 81(19): 10659-10668.
37. Krosky PM, Baek MC, Jahng WJ, et al. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J Virol 2003; 77(14): 7720-7727.
38. Marschall M, Freitag M, Suchy P, et al. The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology 2003; 311(1): 60-71.
39. Izumiya Y, Izumiya C, Van Geelen A, et al. Kaposi's sarcoma-associated herpesvirus-encoded protein kinase and its interaction with K-bZIP. J Virol 2007; 81(3): 1072-1082.
40. Advani SJ, Weichselbaum RR, Roizman B. cdc2 cyclin-dependent kinase binds and phosphorylates herpes simplex virus 1 U(L)42 DNA synthesis processivity factor. J Virol 2001; 75(21): 10326-10333.
41. Smith-Donald BA, Durand LO, Roizman B. Role of cellular phosphatase cdc25C in herpes simplex virus 1 replication. J Virol 2008; 82(9): 4527-4532.
42. Henneke G, Koundrioukoff S, Hubscher U. Multiple roles for kinases in DNA replication. EMBO Rep 2003; 4(3): 252-256.
43. Koundrioukoff S, Jonsson ZO, Hasan S, et al. A direct interaction between proliferating cell nuclear antigen (PCNA) and Cdk2 targets PCNA-interacting proteins for phosphorylation. J Biol Chem 2000; 275(30): 22882-22887.
44. Kawaguchi Y, Matsumura T, Roizman B, Hirai K. Cellular elongation factor 1delta is modified in cells infected with representative alpha-, beta-, or gammaherpesviruses. J Virol 1999; 73(5): 4456-4460.
45. Kawaguchi Y, Van Sant C, Roizman B. Eukaryotic elongation factor 1delta is hyperphosphorylated by the protein kinase encoded by the U(L)13 gene of herpes simplex virus 1. J Virol 1998; 72(3): 1731-1736.
46. Baek MC, Krosky PM, Pearson A, Coen DM. Phosphorylation of the RNA polymerase II carboxylterminal domain in human cytomegalovirusinfected cells and in vitro by the viral UL97 protein kinase. Virology 2004; 324(1): 184-193.
47. Durand LO, Advani SJ, Poon AP, Roizman B. The carboxyl-terminal domain of RNA polymerase II is phosphorylated by a complex containing cdk9 and infected-cell protein 22 of herpes simplex virus 1. J Virol 2005; 79(11): 6757-6762.
48. Long MC, Leong V, Schaffer PA, Spencer CA, Rice SA. ICP22 and the UL13 protein kinase are both required for herpes simplex virus-induced modification of the large subunit of RNA polymerase II. J Virol 1999; 73(7): 5593-5604.
49. Gebara MM, Sayre MH, Corden JL. Phosphorylation of the carboxy-terminal repeat domain in RNA polymerase II by cyclin-dependent kinases is sufficient to inhibit transcription. J Cell Biochem 1997; 64(3): 390-402.
50. Prelich G. RNA polymerase II carboxy-terminal domain kinases: emerging clues to their function. Eukaryot Cell 2002; 1(2): 153-162.
51. Advani SJ, Brandimarti R, Weichselbaum RR, Roizman B. The disappearance of cyclins A and B and the increase in activity of the G(2)/M-phase cellular kinase cdc2 in herpes simplex virus 1-infected cells require expression of the alpha22/U(S)1.5 and U(L)13 viral genes. J Virol 2000; 74(1): 8-15.
52. Advani SJ, Weichselbaum RR, Roizman B. The role of cdc2 in the expression of herpes simplex virus genes. Proc Natl Acad Sci U S A 2000; 97(20): 10996-11001.
53. Baek MC, Krosky PM, He Z, Coen DM. Specific phosphorylation of exogenous protein and peptide substrates by the human cytomegalovirus UL97 protein kinase. Importance of the P+5 position. J Biol Chem 2002; 277(33): 29593-29599.
54. Daikoku T, Shibata S, Goshima F, et al. Purification and characterization of the protein kinase encoded by the UL13 gene of herpes simplex virus type 2. Virology 1997; 235(1): 82-93.
55. Ng TI, Talarico C, Burnette TC, Biron K, Roizman B. Partial substitution of the functions of the herpes simplex virus 1 U(L)13 gene by the human cytomegalovirus U(L)97 gene. Virology 1996; 225(2): 347-358.
56. Wagner M, Michel D, Schaarschmidt P, et al. Comparison between human cytomegalovirus pUL97 and murine cytomegalovirus (MCMV) pM97 expressed by MCMV and vaccinia virus: pM97 does not confer ganciclovir sensitivity. J Virol 2000; 74(22): 10729-10736.
57. Fox DS, Schleiss MR. Sequence and transcriptional analysis of the guinea pig cytomegalovirus UL97 homolog. Virus Genes 1997; 15(3): 255-264.
58. Schleiss M, Eickhoff J, Auerochs S, et al. Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo. Antiviral Res 2008; 79(1): 49-61.
59. Mocarski ES, Jr., Courcelle CT. Cytomegaloviruses and their replication. In Fields Virology (4th edn), Knipe DM, Howley PM (eds). Lippincott, Williams and Wilkins: Philadelphia, PA, 2001; 2629-2673.
60. Davison AJ, Dolan A, Akter P, Addison C, Dargan DJ, Alcendor DJ, McGeoch DJ, Hayward GS. The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J Gen Virol. 2003; 84(Pt 1): 17-28.
61. Wing BA, Huang ES. Analysis and mapping of a family of 30-coterminal transcripts containing coding sequences for human cytomegalovirus open reading frames UL93 through UL99. J Virol. 1995; 69(3): 1521-1531.
62. Chee MS, Bankier AT, Beck S, et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 1990; 154: 125-169.
63. Michel D, Pavic I, Zimmermann A, et al. The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase. J Virol 1996; 70(9): 6340-6346.
64. Varnum SM, Streblow DN, Monroe ME, et al. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol 2004; 78(20): 10960-10966.
65. Michel D, Schaarschmidt P, Wunderlich K, et al. Functional regions of the human cytomegalovirus protein pUL97 involved in nuclear localization and phosphorylation of ganciclovir and pUL97 itself. J Gen Virol 1998; 79(Pt 9): 2105-2112.
66. Prichard MN, Britt WJ, Daily SL, Hartline CB, Kern ER. Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J Viro. 2005; 79(24): 15494-15502.
67. Hume AJ, Finkel JS, Kamil JP, Coen DM, Culbertson MR, Kalejta RF. Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. Science 2008; 320(5877): 797-799.
68. Prichard MN, Sztul E, Daily SL, et al. Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. J Virol 2008; 82(10): 5054-5067.
69. Gill RB, Frederick SL, Hartline CB, Chou S, Prichard MN. Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir. Virol J 2009; 6: 9.
70. Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988; 241(4861): 42-52.
71. Metzger C, Michel D, Schneider K, Luske A, Schlicht HJ, Mertens T. Human cytomegalovirus UL97 kinase confers ganciclovir susceptibility to recombinant vaccinia virus. J Virol 1994; 68(12): 8423-8427.
72. Michel D, Kramer S, Hohn S, Schaarschmidt P, Wunderlich K, Mertens T. Amino acids of conserved kinase motifs of cytomegalovirus protein UL97 are essential for autophosphorylation. J Virol 1999; 73(10): 8898-8901.
73. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 2008; 18(4): 233-246.
74. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 2002; 5(2): 88-114.
75. Marschall M, Stein-Gerlach M, Freitag M, Kupfer R, van Den Bogaard M, Stamminger T. Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97. J Gen Virol 2001; 82(Pt 6): 1439-1450.
76. Cano-Monreal GL, Tavis JE, Morrison LA. Substrate specificity of the herpes simplex virus type 2 UL13 protein kinase. Virology 2008; 374(1): 1-10.
77. Remenyi A, Good MC, Lim WA. Docking interactions in protein kinase and phosphatase networks. Curr Opin Struct Biol 2006; 16(6): 676-685.
78. Biron KK, Fyfe JA, Stanat SC, et al. A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]-methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci U S A 1986; 83(22): 8769-8773.
79. Talarico CL, Burnette TC, Miller WH, et al. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob Agents Chemother 1999; 43(8): 1941-1946.
80. Zimmermann A, Michel D, Pavic I, et al. Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses. Antiviral Res 1997; 36(1): 35-42.
81. Kern ER, Kushner NL, Hartline CB, et al. In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob Agents Chemother 2005; 49(3): 1039-1045.
82. Marschall M, Stein-Gerlach M, Freitag M, Kupfer R, van den Bogaard M, Stamminger T. Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy. J Gen Virol 2002; 83(Pt 5): 1013-1023.
83. Suzutani T, Ogasawara M, Shibaki T, Azuma M. Susceptibility of protein kinase (ORF47)-deficient varicella-zoster virus strains to anti-herpesvirus nucleosides. Antiviral Res 2000; 45(1): 79-82.
84. Scott GM, Ng HL, Morton CJ, Parker MW, Rawlinson WD. Murine cytomegalovirus resistant to antivirals has genetic correlates with human cytomegalovirus. J Gen Virol 2005; 86(Pt 8): 2141-2151.
85. Rawlinson WD, Zeng F, Farrell HE, Cunningham AL, Scalzo AA, Booth TW, Scott GM. The murine cytomegalovirus (MCMV) homolog of the HCMV phosphotransferase (UL97(pk)) gene. Virology 1997; 233(2): 358-363.
86. Williams SL, Hartline CB, Kushner NL, et al. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother 2003; 47(7): 2186-2192.
87. Kern ER. Pivotal role of animal models in the development of new therapies for cytomegalovirus infections. Antiviral Res 2006; 71(2-3): 164-171.
88. Baek MC, Krosky PM, Coen DM. Relationship between autophosphorylation and phosphorylation of exogenous substrates by the human cytomegalovirus UL97 protein kinase. J Virol 2002; 76(23): 11943-11952.
89. Tamrakar S, Kapasi AJ, Spector DH. Human cytomegalovirus infection induces specific hyperphosphorylation of the carboxyl-terminal domain of the large subunit of RNA polymerase II that is associated with changes in the abundance, activity, and localization of cdk9 and cdk7. J Virol 2005; 79(24): 15477-15493.
90. Kapasi AJ, Spector DH. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome. J Virol 2008; 82(1): 394-407.
91. Monnier A, Belle R, Morales J, Cormier P, Boulben S, Mulner-Lorillon O. Evidence for regulation of protein synthesis at the elongation step by CDK1/cyclin B phosphorylation. Nucleic Acids Res 2001; 29(7): 1453-1457.
92. Marschall M, Marzi A, aus dem Siepen P, et al. Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina. J Biol Chem 2005; 280(39): 33357-33367.
93. Hamirally S, Kamil JP, Ndassa-Colday YM, et al. Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog 2009; 5(1): e1000275.
94. Peter M, Nakagawa J, Doree M, Labbe JC, Nigg EA. In vitro disassembly of the nuclear lamina and M phase-specific phosphorylation of lamins by cdc2 kinase. Cell 1990; 61(4): 591-602.
95. Jault FM, Jault JM, Ruchti F, et al. Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. J Virol 1995; 69(11): 6697-6704.
96. Hertel L, Chou S, Mocarski ES. Viral and cell cycle-regulated kinases in cytomegalovirus-induced pseudomitosis and replication. PLoS Pathog 2007; 3(1): e6.
97. Wolf DG, Honigman A, Lazarovits J, Tavor E, Panet A. Characterization of the human cytomegalovirus UL97 gene product as a virion-associated protein kinase. Arch Virol 1998; 143(6): 1223-1232.
98. Wolf DG, Courcelle CT, Prichard MN, Mocarski ES. Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc Natl Acad Sci U S A 2001; 98(4): 1895-1900.
99. Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 2002; 46(8): 2365-2372.
100. Chou S, Van Wechel LC, Marousek GI. Effect of cell culture conditions on the anticytomegalovirus activity of maribavir. Antimicrob Agents Chemother 2006; 50(7): 2557-2559.
101. Krosky PM, Baek MC, Coen DM. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol 2003; 77(2): 905-914.
102. Purves FC, Ogle WO, Roizman B. Processing of the herpes simplex virus regulatory protein alpha 22 mediated by the UL13 protein kinase determines the accumulation of a subset of alpha and gamma mRNAs and proteins in infected cells. Proc Natl Acad Sci U S A 1993; 90(14): 6701-6705.
103. Wolf DG, Yaniv I, Ashkenazi S, Honigman A. Emergence of multiple human cytomegalovirus ganciclovir-resistant mutants with deletions and substitutions within the UL97 gene in a patient with severe combined immunodeficiency. Antimicrob Agents Chemother 2001; 45(2): 593-595.
104. McCormick AL, Roback L, Mocarski ES. HtrA2/ Omi terminates cytomegalovirus infection and is controlled by the viral mitochondrial inhibitor of apoptosis (vMIA). PLoS Pathog 2008; 4(5): e1000063.
105. Heath CM, Windsor M, Wileman T. Aggresomes resemble sites specialized for virus assembly. J Cell Biol 2001; 153(3): 449-455.
106. Wileman T. Aggresomes and autophagy generate sites for virus replication. Science 2006; 312(5775): 875-878.
107. Sanchez V, Spector DH. Virology. CMV makes a timely exit. Science 2002; 297(5582): 778-779.
108. Stewart CL, Roux KJ, Burke B. Blurring the boundary: the nuclear envelope extends its reach. Science. 2007; 318(5855): 1408-1412.
109. Muranyi W, Haas J, Wagner M, Krohne G, Koszinowski UH. Cytomegalovirus recruitment of cellular kinases to dissolve the nuclear lamina. Science 2002; 297(5582): 854-857.
110. Milbradt J, Auerochs S, Marschall M. Cytomegaloviral proteins pUL50 and pUL53 are associated with the nuclear lamina and interact with cellular protein kinase C. J Gen Virol 2007; 88(Pt 10): 2642-2650.
111. Mettenleiter TC. Herpesvirus assembly and egress. J Virol 2002; 76(4): 1537-1547.
112. Das S, Vasanji A, Pellett PE. Three-dimensional structure of the human cytomegalovirus cytoplasmic virion assembly complex includes a reoriented secretory apparatus. J Virol 2007; 81(21): 11861-11869.
113. Sanchez V, Greis KD, Sztul E, Britt WJ. Accumulation of virion tegument and envelope proteins in a stable cytoplasmic compartment during human cytomegalovirus replication: characterization of a potential site of virus assembly. J Virol 2000; 74(2): 975-986.
114. Azzeh M, Honigman A, Taraboulos A, Rouvinski A, Wolf DG. Structural changes in human cytomegalovirus cytoplasmic assembly sites in the absence of UL97 kinase activity. Virology 2006; 354(1): 69-79.
115. Bain M, Sinclair J. The S phase of the cell cycle and its perturbation by human cytomegalovirus. Rev Med Virol 2007; 17(6): 423-434.
116. Castillo JP, Kowalik TF. Human cytomegalovirus immediate early proteins and cell growth control. Gene 2002; 290(1-2): 19-34.
117. Sanchez V, Spector DH. Subversion of cell cycle regulatory pathways. Curr Top Microbiol Immunol 2008; 325: 243-262.
118. Fortunato EA, McElroy AK, Sanchez I, Spector DH. Exploitation of cellular signaling and regulatory pathways by human cytomegalovirus. Trends Microbiol 2000; 8(3): 111-119.
119. Bresnahan WA, Boldogh I, Thompson EA, Albrecht T. Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1. Virology 1996; 224(1): 150-160.
120. Dittmer D, Mocarski ES. Human cytomegalovirus infection inhibits G1/S transition. J Virol 1997; 71(2): 1629-1634.
121. Lu M, Shenk T. Human cytomegalovirus infection inhibits cell cycle progression at multiple points, including the transition from G1 to S. J Virol 1996; 70(12): 8850-8857.
122. Wiebusch L, Uecker R, Hagemeier C. Human cytomegalovirus prevents replication licensing by inhibiting MCM loading onto chromatin. EMBO Rep 2003; 4(1): 42-46.
123. Cobrinik D. Pocket proteins and cell cycle control. Oncogene 2005; 24(17): 2796-2809.
124. Kitagawa M, Higashi H, Jung HK, et al. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J 1996; 15(24): 7060-7069.
125. Andrei G, De Clercq E, Snoeck R. Novel inhibitors of human CMV. Curr Opin Investig Drugs 2008; 9(2): 132-145.
126. De Clercq E. New inhibitors of human cytomegalovirus (HCMV) on the horizon. J Antimicrob Chemother 2003; 51(5): 1079-1083.
127. Emery VC, Hassan-Walker AF. Focus on new drugs in development against human cytomegalovirus. Drugs 2002; 62(13): 1853-1858.
128. Griffiths PD, Walter S. Cytomegalovirus. Curr Opin Infect Dis 2005; 18(3): 241-245.
129. Whitley RJ. Congenital cytomegalovirus infection: epidemiology and treatment. Adv Exp Med Biol 2004; 549: 155-160.
130. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006; 71(2-3): 154-163.
131. Herget T, Marschall M. Recent developments in anti-herpesviral therapy based on protein kinase inhibitors. In New Concepts of Antiviral Therapy, Bogner E, Holzenburg A (eds). Springer: Berlin, Germany, 2006; 351-371.
132. Mercorelli B, Sinigalia E, Loregian A, Palu G. Human cytomegalovirus DNA replication: antiviral targets and drugs. Rev Med Virol 2008; 18(3): 177-210.
133. Zimmermann A, Wilts H, Lenhardt M, Hahn M, Mertens T. Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase. Antiviral Res 2000; 48(1): 49-60.
134. Herget T, Freitag M, Morbitzer M, Kupfer R, Stamminger T, Marschall M. Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity. Antimicrob Agents Chemother 2004; 48(11): 4154-4162.
135. Drach JC, Townsend LB, Bogner E. Benzimidazoled-ribonucleosides as antiviral agents that target hcmv terminase. In New Concepts of Antiviral Therapy, Bogner E, Holzenburg A (eds). Springer: New York City, 2006.
136. Townsend LB, Devivar RV, Turk SR, Nassiri MR, Drach JC. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)-benzimidazoles. J Med Chem 1995; 38(20): 4098-4105.
137. Biron K. Maribavir: a promising new antiherpes therapeutic agent. In New Concepts of Antiviral Therapy, Bogner E, Holzenburg A (eds). Springer: New York City, 2006.
138. Koszalka GW, Johnson NW, Good SS, et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 2002; 46(8): 2373-2380.
139. Lalezari JP, Aberg JA, Wang LH, et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother 2002; 46(9): 2969-2976.
140. Ma JD, Nafziger AN, Villano SA, Gaedigk A, Bertino JS, Jr. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother 2006; 50(4): 1130-1135.
141. Chou S, Marousek GI. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J Virol 2008; 82(1): 246-253.
142. Chou S, Waldemer RH, Senters AE, et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 2002; 185(2): 162-169.
143. Chou S, Wechel LC, Marousek GI. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J Infect Dis 2007; 196(1): 91-94.
144. McSharry JJ, McDonough A, Olson B, Talarico C, Davis M, Biron KK. Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clin Diagn Lab Immunol 2001; 8(6): 1279-1281.
145. Evers DL, Komazin G, Shin D, Hwang DD, Townsend LB, Drach JC. Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus. Antiviral Res 2002; 56(1): 61-72.
146. Chou S, Marousek GI. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob Agents Chemother 2006; 50(10): 3470-3472.
147. Chou S, Marousek GI, Senters AE, Davis MG, Biron KK. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J Virol 2004; 78(13): 7124-7130.
148. Komazin G, Ptak RG, Emmer BT, Townsend LB, Drach JC. Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J Virol 2003; 77(21): 11499-11506.
149. Prichard MN, Quenelle DC, Bidanset DJ, et al. Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice. Virol J 2006; 31: 8.
150. Sanchez V, Angeletti PC, Engler JA, Britt WJ. Localization of human cytomegalovirus structural proteins to the nuclear matrix of infected human fibroblasts. J Virol 1998; 72(4): 3321-3329.